Shareprice
18 Apr 2024

Press & news

FluoGuide develops surgical solutions that is expected to reduce suffering for the patient and increases the likelihood of cure as well as reducing costs for the health care system.

New - New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

Presentation of phase l/lla clinical data of FG001 in aggressive brain cancer at the European Congress of Neurosurgery 2022

Press release


October 6, 2022

Copenhagen, Denmark, 6 October 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to inform that the Principal Investigator, Chief Surgeon Jane Skjøth-Rasmussen will be presenting the outstanding clinical data from the completed phase I/IIa trial with FG001 in patients with aggressive brain cancer undergoing surgery at the European Congress of Neurosurgery on 19 October 2022 in Belgrade, Serbia.

The excellent phase l/lla clinical data of FG001 in aggressive brain cancer will be presented by Principal Investigator and Chief Surgeon Jane Skjøth-Rasmussen at the European Congress of Neurosurgery in Belgrade, facilitated by the European Association of Neurosurgical Societies (EANS).

The purpose of the trial was to investigate FG001 for intraoperative visualization of malignant glioma in patients scheduled for neurosurgery. The full abstract can be found here.

Based on the promising clinical data, FG001 is advanced into a phase IIb trial in aggressive brain cancer where the top line result is expected in H1 2023.

For further information, please contact:

Morten Albrechtsen, CEO,
FluoGuide A/S
+45 24 25 62 66,
ma@fluoguide.com

Certified Adviser:
Svensk Kapitalmarknadsgransking AB
Phone: +46 70 755 95 51
E-mail: ca@skmg.se

About FluoGuide
FluoGuide’s primary focus is to maximize surgical outcomes in oncology. The Company’s lead product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. The improved precision enabled by FluoGuide’s products has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, the improved precision will improve a patient’s chance of achieving a complete cure and will lower system-wide healthcare costs. The Company is has demonstrated efficacy of F001 as well as it to be well tolerated and safe in the proof-of-concept clinical study (phase I/II) in patients with high grade glioma undergoing surgery. FluoGuide has decided to explore FG001 in three other severe cancer indications, namely lung, head & neck, meningioma and low grade glioma. FluoGuide is listed on Nasdaq First North Sweden under the ticker “FLUO”.

For more information on the Company’s uPAR technology platform and our pipeline please visit our home page www.fluoguide.com

This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 954904.